Abbott Labs (ABT) PT Lowered to $151 but Morgan Stanley Sees an Improved Balance Sheet and Post Covid Growth Profile
Tweet Send to a Friend
Morgan Stanley analyst Cecilia Furlong lowered the price target on Abbott Labs (NYSE: ABT) to $151.00 (from $157.00) after 4Q ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
